Abstract
The immune system is a complex network of metabolic pathways and cells, which are designed to distinguish harmful insults from harmless changes or fluctuations in metabolism and to mount an appropriate response to these harmful insults without compromising the affected tissue. Therefore, it walks a fine line to combat pathogens and cellular transformation on the one hand and to tolerate commensals on mucosal surfaces (such as normal gut bacteria), and food components, on the other hand.
Access provided by Autonomous University of Puebla. Download chapter PDF
Similar content being viewed by others
Keywords
- Major Histocompatibility Complex
- Major Histocompatibility Complex Class
- Major Histocompatibility Complex Molecule
- Follicular Dendritic Cell
- Secondary Lymphoid Organ
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Anatomy and Physiology of the Immune System
The immune system is a complex network of metabolic pathways and cells, which are designed to distinguish harmful insults from harmless changes or fluctuations in metabolism and to mount an appropriate response to these harmful insults without compromising the affected tissue. Therefore, it walks a fine line to combat pathogens and cellular transformation on the one hand and to tolerate commensals on mucosal surfaces (such as normal gut bacteria), and food components, on the other hand.
Moreover, it has evolved to specifically meet the challenges of its respective host species concerning pathogens encountered in the ecological niche that the host occupies and during the time of reproduction that has to be protected to guarantee propagation of the species. Therefore, the differences even between closely related mammalian species are considerable, placing the immune system in third position of the most divergent organs between mouse and man [1, 2].
These challenges are met by the immune system with stringent education of its components to ignore the physiological state (which happens in so-called primary lymphoid organs such as the thymus or bone marrow) and by integration of afferent information (which happens in immunological decision centers, the secondary and tertiary lymphoid tissues such as spleen or lymph nodes). Concomitantly, efferent responses (cellular and humoral) to target harmful insults are mounted.
All soluble factors directed at insults are called humoral immune responses. These include invariant molecules like antimicrobial peptides or the alternative pathway of complement system and molecules of the adaptive immune system, mainly antibodies. The complement activation is part of the innate immune system and establishes pores in targeted cells (cell lysis), enhances phagocytosis of antigens (opsonization), and attracts macrophages and neutrophils (chemotaxis).
Antibodies are selected from a large repertoire that is generated by (1) somatic DNA recombination and then further shaped to recognize the targeted antigen with higher affinity and (2) additional effector mechanisms such as somatic hypermutation and class switch recombination, producing different subtypes of immunoglobulins (Ig).
The cellular immune responses include activation of cytotoxic effector cells and phagocytes. Again these responses can be innate (including natural killer cells and pathogen recognition by phagocytes, such as macrophages, using scavenger receptors), or they can be adaptive (including cytotoxic T cells and T-cell activation of phagocytes). Therefore, the immune system has a large armamentarium to restore the healthy steady state.
Specific Pathways and Metabolic Processes of the Immune System and Its Cells
Primary Lymphoid Tissues
The main primary lymphoid tissues are the thymus and the bone marrow, where T cells and B cells (also known as T and B lymphocytes) are educated, respectively. T cells can detect changes (such as the presence of foreign proteins) inside cells, whereas B cells secrete effector molecules, mainly antibodies to target extracellular pathogens. Selectivity of T and B cells is achieved by somatic recombination of their respective antigen receptor genes, followed by a stringent selection process to ensure they carry functional receptors, which do not recognize self-structures, such as endogenous proteins or sugar moieties on the surface of host cells [3, 4].
B cells develop from hematopoietic precursors in the bone marrow and are deleted by apoptosis if they fail to generate a functional antibody on their surface (see below) and also if this antibody recognizes self-structures in the bone marrow.
T cells originate from precursors that also develop in the bone marrow, but then migrate to the thymus. There, only T cells continue to develop, whose T-cell receptors recognize major histocompatibility complex (MHC) molecules, which in humans are also called human leukocyte antigen (HLA) molecules. These scaffolding proteins display products of the protein and lipid catabolism of thymic epithelial cells to the T cells. After this positive selection, T cells are eliminated by negative selection if they strongly react to MHC molecules that present self-structures, thus generating a central tolerance. In general, both cluster of differentiation 4-positive (CD4+) T-helper (Th) cells and CD8+ cytotoxic T cells develop that recognize foreign structures, in particular extracellular and intracellular peptides, on MHC class II and class I molecules, respectively.
Secondary Lymphoid Tissues
Once the mature and educated T and B cells emerge from primary lymphoid organs, they home to secondary lymphoid organs like spleen, lymph nodes, tonsils, and gut mucosa-associated lymphoid tissues via the blood stream. In the secondary lymphoid organs, they extravasate from the blood in specialized endothelia, called high endothelial venules, in response to gradients of chemokines, attractants for migration, such as chemokine (C-C motif) ligand (CCL) 19 and 21 (Fig. 1).
For activation of T cells, processed foreign structures (mostly peptides) are presented on MHC molecules by dendritic cells (DCs) that have picked up these antigens at various sites of the body in order to carry them to secondary lymphoid tissues via afferent lymphatic vessels (Fig. 1) [5]. This antigen transport occurs from all organs, and therefore a dense network of secondary lymphoid tissues weaves through the body to keep the antigen transport times short. Once a T cell detects a specific antigen, it proliferates and differentiates.
T cells differentiate into effector cells, e.g., Th1, Th2, or Th17 cells, which secrete different sets of cytokines to communicate with other immune and somatic cells, or into memory cells, which will continue to migrate through secondary lymphoid tissues and promptly respond by proliferation and defense mechanisms, in case the antigen comes back (Fig. 1).
Upon activation by cognate antigen recognition, B cells enter germinal centers in secondary lymphoid tissues [6]. At these sites, they mature their antigen receptor by somatic hypermutation (called affinity maturation) in order to produce antibodies that bind foreign structures called antigens with higher avidity. At the same time, they switch their antibody molecule isotype, e.g., from IgM to IgG, allowing them to acquire additional effector functions, like binding to Fc receptors on phagocytes, follicular dendritic cells, or cytotoxic cells and complement fixation. Only if the altered antibody still recognizes the antigen (signal 1), e.g., presented bound to the complement or Fc receptors on follicular dendritic cells, and the B cell receives signals (“help”) from a T cell (that in most cases has to recognize the same antigen but in a processed form preferential on MHC molecules, signal 2), the B cell survives this germinal center reaction and can go on to develop into a memory B cell or an antibody-secreting plasma cell.
T and B cells emigrate from secondary lymphoid tissues via the efferent lymphatics to the sites of the harmful insult guided by chemokine gradients, like the chemokine (C-X-C motif) ligand (CXCL) 9 and CXCL10 (Fig. 1). This process of immune response initiation is called priming.
Tertiary Lymphoid Tissues
In order to keep the distances for immune cell migration short and therefore the response time to a minimum, tertiary lymphoid tissues develop at sites of chronic immune cell infiltrates and inflammation [7]. These are similar in structure and function to secondary lymphoid tissues.
Outside-In: Communication of Stromal Cells with Immune Cells
The afferent arm of immune responses is mainly represented by DCs, which continuously report the immunological health of organs to secondary lymphoid tissues by transporting organ constituents and the conditions, under which they have acquired these as their surface molecule phenotype and cytokine secretion pattern. They can detect pathogens in all organs directly via receptors for pathogen-associated molecular patterns (PAMPs), such as bacterial cell wall components, viral unmethylated DNA, and viral RNA, which activate them. Alternatively, they can also detect organ or tissue destruction indicated by the release of danger-associated molecular pattern (DAMPs) [8, 9], like ureate crystals as well as extracellular high mobility group B1 protein and ATP release (Fig. 2). Some of these are recognized by inflammasomes, of which the NLRP3 containing protein complex is the best studied [8]. Their activation allows interleukin 1 (IL-1) production, which is the main mediator of inflammation causing heat, redness, pain, swelling, and loss of tissue function. Both, PAMPS and DAMPs, thus activate DC migration and immune response priming in secondary lymphoid organs. In addition, stromal cells can communicate with DCs via chemokines and cytokines. Therefore, the input by the organ environment is crucial for the afferent communication of the immune system with secondary lymphoid organs.
Inside-In: Communication Between Immune Cells
Chemokines (chemotactic cytokines), such as CXCL9 and CXCL10, are produced to build gradients in tissues to attract immune cells such as effector T cells. Immune cells (such as macrophages and T cells) communicate with each other and stromal cells through surface receptors that accumulate at membrane contact areas, so-called immunological synapses. Cytokines, e.g., interferon γ (IFNγ), are secreted into these synapses or to neighboring cells to further refine the communication between immune cells.
Three signals constitute the core of the communication between immune cells, which primarily happens in secondary lymphoid tissues between antigen carrying DCs and responding T cells (Fig. 2). The first signal is the presentation of catabolic products of antigens (mainly peptides) by DCs on MHC molecules to the T-cell receptor of T cells. These peptides originate from the two main proteolytic machineries of the cell, i.e., lysosomes and proteasomes [10]. Proteasomal products are presented on MHC class I molecules to cytotoxic CD8+ T cells, whereas lysosomal products are presented on MHC class II molecules to helper CD4+ T cells, which assist maintenance and differentiation of both primed CD8+ T and B cells. This first signal induces proliferation of T cells, only if co-stimulatory signals (see below) are present. If these signals are absent, the antigen-specific T cells are eliminated after a few cell divisions, a process contributing to peripheral tolerance [11].
Thus, activated DCs save the proliferating T cells from dying by releasing cytokines and other co-stimulatory molecules, like IL-12 and IL-15, toward them, and shape their profile [12]. These cytokines imprint information about the conditions, under which DCs have been activated, onto the responding T cell. For example, IL-12 favors the development of Th1 polarized T cell responses and is mainly secreted by DCs after virus encounter. A Th1 response can trigger the destruction of virus-infected cells by cytotoxic T cells. Furthermore, this so-called polarization also gives CD4+ T cells a certain profile of chemokine receptors that will direct them to the tissues, in which the DCs had been activated. For example, the C-C chemokine receptor type 9 is required for homing CD4+ T cells to the gut [13], while CD8+ T cells acquire a less variant chemokine receptor repertoire that will direct them to sites of inflammation. There, a tailored response is mounted, including the secretion of cytokines, acting on the infected or transformed tissue, e.g., IFNγ to inhibit viral replication, and the expression of cytotoxic molecules, e.g., perforin-1, to directly destroy the diseased cells.
Distinct metabolic pathways, such as macroautophagy [14], are required for T-cell proliferation [15], which also occurs locally in infected tissues, presumably to further amplify the T-cell response. Oxidative phosphorylation generates most ATP in resting T cells. However, activated T cells dramatically increase their rates of glycolysis and lactate production. Importantly, glucose is strictly required for T-cell proliferation and cytokine production, even when other metabolic substrates such as glutamine or fatty acids are present, likely due to the ability of glucose metabolism to consistently generate ATP and NADPH and stabilize antiapoptotic proteins [16]. Moreover, aerobic glycolysis is necessary for T-cell effector function, in particular for IFNγ production [17]. Finally, whereas most T cells rely on glycolysis, a subset of T cells (such as regulatory T cells, also called Treg, or CD8+ memory T cells) requires fatty acid oxidation, showing that energy metabolism influences immune responses [16].
Inside-Out: Communication of Immune Cells with Stromal Cells
The effector molecules from polarized T cells are then able to change tissue homeostasis in the inflamed and/or infected organs, from which the DCs carried the antigens to the secondary lymphoid organs. A wide variety of responses can be elicited, ranging from metabolic changes in target cells to release of antimicrobial peptides, or to induction of apoptosis. Metabolic changes aim to make cells less hospitable for infectious agents and reduce pathogen replication. For example, IFNs can induce an antiviral state in part by inhibiting anabolic pathways required for virus production [18]. Secretion of antimicrobial peptides by epithelial cells at mucosal surfaces is stimulated by IL-22, which is either secreted by innate lymphoid cells or Th17 polarized CD4+ T cells [19]. Cell death can be triggered by cytotoxic CD8+ T cells via perforin-mediated granzyme injection into an infected target cell. During this process, at least one of the cell death initiating proteases of the granzyme family enters the target cell through pores that are formed by perforin. Alternatively, a cytotoxic T cell kills an infected or transformed cell by activation of its cell death receptors (Fig. 2) [20]. Thus, immune cells can dramatically change cellular physiology within an inflamed organ.
Miscommunication in the Immune System as the Basis of Disease
The borderline between hyporesponsiveness of the immune system resulting in susceptibility to disease [21] and hyperresponsiveness leading to immunopathology and autoimmunity [22] is not easily defended by the immune system and drawn by the genetic makeup of the individual. Any significant insult that releases DAMPs can change the organ environment and metabolism so that it is no longer recognized as self by the immune system. This is in part explained by the circumstance that the lymphocytes were educated toward a different steady state. Sometimes the resulting autoimmune responses are transient, just causing immunopathology during the infectious or traumatic insult. However, sometimes, but fortunately rarely, they result in self-perpetuating autoimmune disease [22], depending in part on the genetic variation of the affected individuals (see, e.g., chapters “Rheumatoid arthritis” and “Diabetes mellitus”).
Final Remarks
The key physiological function of the immune system is to defend multicellular organisms against harmful “nonself” by transporting information from organs to secondary lymphoid tissues and mounting immune responses when this information indicates infection or tissue damage. Both overshooting (see chapter “Rheumatoid arthritis”) and too cautious immune reactions (see chapter “Community-acquired pneumonia”) lead to disease and are caused by the combination of the individual’s genetic predisposition and the environmental conditions.
References
Waterston RH, Lindblad-Toh K, Birney E, Rogers J, Abril JF, Agarwal P et al (2002) Initial sequencing and comparative analysis of the mouse genome. Nature 420:520–562
Seok J, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, Xu W, Richards DR, McDonald-Smith GP, Gao H, Hennessy L, Finnerty CC, López CM, Honari S, Moore EE, Minei JP, Cuschieri J, Bankey PE, Johnson JL, Sperry J, Nathens AB, Billiar TR, West MA, Jeschke MG, Klein MB, Gamelli RL, Gibran NS, Brownstein BH, Miller-Graziano C, Calvano SE, Mason PH, Cobb JP, Rahme LG, Lowry SF, Maier RV, Moldawer LL, Herndon DN, Davis RW, Xiao W, Tompkins RG (2013) Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci U S A 110:3507–3512
Kyewski B, Klein L (2006) A central role for central tolerance. Annu Rev Immunol 24:571–606
Jankovic M, Casellas R, Yannoutsos N, Wardemann H, Nussenzweig MC (2004) RAGs and regulation of autoantibodies. Annu Rev Immunol 22:485–501
Cyster JG (2005) Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs. Annu Rev Immunol 23:127–159
Victora GD, Nussenzweig MC (2012) Germinal centers. Annu Rev Immunol 30:429–457
van de Pavert SA, Mebius RE (2010) New insights into the development of lymphoid tissues. Nat Rev Immunol 10:664–674
Martinon F, Mayor A, Tschopp J (2009) The inflammasomes: guardians of the body. Annu Rev Immunol 27:229–265
Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ (2010) HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol 28:367–388
Trombetta ES, Mellman I (2005) Cell biology of antigen processing in vitro and in vivo. Annu Rev Immunol 23:975–1028
Steinman RM, Hawiger D, Nussenzweig MC (2003) Tolerogenic dendritic cells. Annu Rev Immunol 21:685–711
Steinman RM (2012) Decisions about dendritic cells: past, present, and future. Annu Rev Immunol 30:1–22
Sallusto F, Mackay CR, Lanzavecchia A (2000) The role of chemokine receptors in primary, effector, and memory immune responses. Annu Rev Immunol 18:593–620
Münz C (2009) Enhancing immunity through autophagy. Annu Rev Immunol 27:423–429
Gerriets VA, Rathmell JC (2012) Metabolic pathways in T cell fate and function. Trends Immunol 33:168–173
Wahl DR, Byersdorfer CA, Ferrara JL, Opipari AW Jr, Glick GD (2012) Distinct metabolic programs in activated T cells: opportunities for selective immunomodulation. Immunol Rev 249:104
Chang CH, Curtis JD, Maggi LB Jr, Faubert B, Villarino AV, O’Sullivan D, Huang SC, van der Windt GJ, Blagih J, Qiu J, Weber JD, Pearce EJ, Jones RG, Pearce EL (2013) Posttranscriptional control of T cell effector function by aerobic glycolysis. Cell 153:1239–1251
MacMicking JD (2012) Interferon-inducible effector mechanisms in cell-autonomous immunity. Nat Rev Immunol 12:367–382
Sonnenberg GF, Fouser LA, Artis D (2011) Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22. Nat Immunol 12:383–390
Lopez JA, Brennan AJ, Whisstock JC, Voskoboinik I, Trapani JA (2012) Protecting a serial killer: pathways for perforin trafficking and self-defence ensure sequential target cell death. Trends Immunol 33:406–412
Casanova JL, Abel L, Quintana-Murci L (2011) Human TLRs and IL-1Rs in host defense: natural insights from evolutionary, epidemiological, and clinical genetics. Annu Rev Immunol 29:447–491
Münz C, Lunemann JD, Getts MT, Miller SD (2009) Antiviral immune responses: triggers of or triggered by autoimmunity? Nat Rev Immunol 9:246–258
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag Wien
About this chapter
Cite this chapter
Münz, C. (2014). Overview. In: Lammert, E., Zeeb, M. (eds) Metabolism of Human Diseases. Springer, Vienna. https://doi.org/10.1007/978-3-7091-0715-7_44
Download citation
DOI: https://doi.org/10.1007/978-3-7091-0715-7_44
Published:
Publisher Name: Springer, Vienna
Print ISBN: 978-3-7091-0714-0
Online ISBN: 978-3-7091-0715-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)